Combination of cloud-based technology, 340B program management and EnlivenHealth® patient engagement solutions will drive key initiatives for the Texas-based healthcare system
MOUNTAIN VIEW, Calif., February 14, 2022–(BUSINESS WIRE)–Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and compliance tools for healthcare systems and pharmacies, today announced that UMC Health System ( “UMC”) in Lubbock, Texas selected Omnicell Solutions’ comprehensive portfolio of advanced services to support key pharmacy initiatives, including acute care, ambulatory care, retail and 340B program strategies.
UMC has signed a 10-year single-source agreement for Omnicell’s portfolio of cloud-based solutions, including central pharmacy automation and point-of-care dispensing systems. The partnership is also expected to support UMC’s goals of expanding community pharmacy services through opportunities with Omnicell’s 340B services and EnlivenHealth’s patient engagement solutions, helping UMC improve operational efficiencies in its continuum of care. Most importantly, these solutions will allow pharmacy staff and clinicians to focus on higher value tasks that support patient safety.
As a public hospital with a 40-year mandate supporting the Lubbock community, UMC has seen an increase in demand for its services. According to US Census data, Texas has one of the highest uninsured population rates – at 18.4% in 2019, nearly double the national average.1 Programs like the federal 340B drug pricing program and patient engagement technology solutions aim to help improve health outcomes for these underserved communities.
“At UMC, our top priority is patient safety and ensuring healthy outcomes for our community,” said John Lowe, vice president of support services at UMC Health System. “In partnership with Omnicell, we are developing an advanced pharmaceutical technology strategy that aligns with our vision to streamline and advance pharmacy and nursing practice across our system. Most importantly, we are laying a technological foundation that will enable the best patient care.
UMC has embraced the industry-defined vision of autonomous pharmacy, a roadmap designed to develop a fully automated, error-free medication management infrastructure. Through automation, intelligence, and expert services, the autonomous pharmacy is expected to drive performance and outcomes, and allow clinicians to focus on manual administrative functions toward patient support needs.
“As medication management becomes more complex, we believe healthcare systems need end-to-end cloud solutions that will enable them to work smarter, while supporting safe and effective pharmaceutical care,” said Scott Seidelmann , Executive Vice President and Chief Commercial Officer. officer at Omnicell. “We are confident that Omnicell’s partnership with UMC will provide comprehensive solutions that connect acute and ambulatory care to help improve performance and that are designed to deliver the highest levels of patient safety across the entire healthcare system. health.”
To learn more about Omnicell’s innovative approach to empowering clinicians through medication management, visit omnicell.com.
UMC Health System is an award-winning national healthcare system comprised of more than 4,600 team members and more than 30 locations of care. We are proud to partner with Texas Tech University Health Sciences Center to provide the best care in West Texas and East New Mexico. Whether you’re managing a chronic illness, coping with an unexpected illness, or simply working to stay healthy, we’re passionate about your well-being and helping you stay that way. At UMC, our passion is you.
Since 1992, Omnicell has been committed to transforming the pharmaceutical care delivery model to dramatically improve outcomes and reduce costs. Through the autonomous pharmacy vision, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across care contexts. Healthcare organizations around the world use Omnicell automation and analytics solutions to increase operational efficiency, reduce medication errors, provide actionable insights and improve patient safety. Institutional and retail pharmacies across North America and the UK are leveraging Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and prescription compliance, helping to reduce costly hospital readmissions. To learn more, visit omnicell.com.
OMNICELL, the Omnicell logo and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Certain statements in this press release relate to future plans and expected benefits and objectives regarding Omnicell’s products and services, including expectations regarding central pharmacy point-of-service automation and dispensing systems based on the Omnicell’s cloud, comprehensive portfolio of advanced services, Omnicell Services’ 340B program management and EnlivenHealth’s SaaS-based patient engagement solutions, as well as transforming the pharmacy care delivery model into a vision defined by the industry Autonomous pharmacy (and any implied financial impact in connection with the above). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ materially from those contemplated by the forward-looking statements due to numerous factors that involve substantial known and unknown risks. and uncertainties, some of which are beyond our control. These risks and uncertainties include, among others, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and to develop and market new and improve existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication compliance solutions market, ( (iv) general adverse economic and market conditions or reduced demand for our solutions, (v) risks relating to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and subscription-based services, and its ability to acquire companies, businesses or technologies and to successfully integrate such acquisitions, (vi) any disruption in information information of Omnicell’s technology systems and data security breaches or cyberattacks on its systems or solutions, (vii) Omnicell’s ability to protect its intellectual property, (viii) Omnicell’s ability to respond to requests or to maintain relationships with its institutional, retail and specialty pharmaceutical customers, (ix) risks relating to the availability and sources of raw materials and components or price fluctuations, shortages or interruptions in supply, ( (x) Omnicell’s dependence on a limited number of suppliers for certain components, equipment and raw materials, as well as technologies provided by third-party suppliers, and (xi) other risks and uncertainties described in more detail in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as in other Omnicell reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell undertakes no obligation to update these statements publicly, or to update why actual results could differ materially from those expressed or implied in the forward-looking statements, whether as a result of changes in circumstances, new information, future events or otherwise, except as required by law.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220214005624/en/
Vice President, Trade Marketing